Ahmadinejad Zahra, Abdi Liae Zahra, Salehizadeh Saideh, Mansori Sedighe, Alijani Neda
Department of Infectious Diseases, Imam Khomeini Complex Hospital, Tehran University of Medical Sciences, Tehran, IR Iran.
Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran.
Iran J Pediatr. 2016 May 21;26(3):e5979. doi: 10.5812/ijp.5979. eCollection 2016 Jun.
Hepatitis B infection is a universal concern. This infection can lead to chronic liver disease and hepatocellular carcinoma. Neonates born to HBsAg-positive mothers are at high risk of chronic hepatitis B virus (HBV) infection, especially for HBeAg-positive mothers or neonates who have not received hepatitis B immunoglobulin (HBIg) and HBV vaccines.
The aim of this study was to evaluate the efficacy of post-exposure prophylaxis in these infants to prevent infection.
Thirty-eight infants born to HBsAg-positive mothers between September 2006 and September 2013 were followed. The investigation evaluated whether the standard prevention protocol of neonatal HBV transmission including HBIg at birth and receiving three doses of vaccine at birth and 2 and 6 months of age was performed, followed by post-vaccination tests (evaluation of HBsAg and HBsAb titer at 9 to 18 months of age) to determine subsequent infection. HBsAb titer ≥ 10 was considered as criterion for effectiveness of the prophylaxis procedure. The acquired data were analyzed using SPSS software (Version 18). The results are reported in descriptive tabulations.
Ninety seven percent (97%) of infants received HBIg at birth in the hospital. Generally, all of them received the first, second and third doses of vaccine at birth, 2 months, and 6 months after birth, respectively. Information for 35 mothers infected with HBV and 38 infants was available. The mean age of the mothers was 30.3 years. The results indicated that 20% of mothers were HBeAg positive. HBsAg was positive in one (2.6%) infant born to an HBeAg-positive mother. Around 94% of infants' HBsAb titers were ≥ 10, and 5.8% were reported as non-responders.
The vertical transmission prevention program used in the study population in Tehran, which had an appropriate sample size, is effective. Additional doses of the vaccine can be useful in raising the effectiveness of immunoprophylaxis for infants at high risk of HBV infection. Also, emphasis must be set on post-vaccination testing.
乙型肝炎感染是一个普遍关注的问题。这种感染可导致慢性肝病和肝细胞癌。母亲为乙肝表面抗原(HBsAg)阳性的新生儿感染慢性乙型肝炎病毒(HBV)的风险很高,尤其是母亲为乙肝e抗原(HBeAg)阳性或未接受乙肝免疫球蛋白(HBIg)和乙肝疫苗的新生儿。
本研究旨在评估这些婴儿暴露后预防感染的效果。
对2006年9月至2013年9月期间母亲为HBsAg阳性的38名婴儿进行随访。调查评估是否执行了新生儿HBV传播的标准预防方案,包括出生时注射HBIg以及在出生时、2个月和6个月时接种三剂疫苗,随后进行接种后检测(在9至18个月龄时评估HBsAg和乙肝表面抗体(HBsAb)滴度)以确定后续感染情况。HBsAb滴度≥10被视为预防措施有效的标准。使用SPSS软件(版本18)对获取的数据进行分析。结果以描述性表格形式报告。
97%的婴儿在医院出生时接受了HBIg。一般来说,他们所有人分别在出生时、出生后2个月和6个月接受了第一剂、第二剂和第三剂疫苗。获得了35名感染HBV母亲和38名婴儿的信息。母亲的平均年龄为30.3岁。结果表明,20%的母亲HBeAg呈阳性。一名母亲为HBeAg阳性的婴儿(2.6%)HBsAg呈阳性。约94%的婴儿HBsAb滴度≥10,5.8%被报告为无反应者。
德黑兰研究人群中使用的垂直传播预防方案样本量合适,是有效的。额外剂量的疫苗可能有助于提高对HBV感染高危婴儿免疫预防的有效性。此外,必须重视接种后检测。